

Performance in Delivering Clinical Trial Research Q1 2022 - 2023
Time to Target (Commercial Contracts)
Studies that have Closed to Recruitment in the Previous 12 months

Research Ethics Number	IRAS number	Name of Trial	Target Number of Patients Agreed?	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Target Date to Recruit Patients Agreed?	Date Agreed to Recruit Target No of Patients	Total Recruited by Agreed Target Date	Recruitment end date	Total Number of Study Participants Recruited	Trial Status	Target met	Comments
18/EM/0061	242931	ALK3831-A307 Effect of ALKS3831 vs Olanzapine on body weight (ENLIGHTEN (MENT 34817))	Range Agreed	3	10	Date Agreed	13/08/2021	2	13/09/2021	3	Recruitment Finished	Yes	
20/NS/0029	277157	Real-world evidence study of primary care referrals to NHS memory clinics and the clinical and economic case for the adoption of the Integrated Cognitive Assessment to improve the dementia diagnosis pathway (ADePT)	Number Agreed	20	20	Date Agreed	30/09/2021	7	30/09/2021	7	Recruitment Finished	Yes	The total recruitment number was incorrect in the Q3 PID returns. There are two main reasons for this study under-recruiting: a delayed start that left a very short recruitment window and the difficulty of getting other referral sites on board due to their traige system (the study design did not fit well with our memory clinics procedures).
20/SW/0086	1003226	A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BII8104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)	Number Agreed	2	2	Date Agreed	31/12/2021	1	31/12/2021	1	Recruitment Finished	No	Difficult study to recruit to. Stable and motivated participants were needed and many patients approached did not want to risk destabilising themselves when participating in the study. There was a high staff turn over and therefore, re-training staff was a necessity which further delayed the recruitment process.
18/EM/0062	242930	ALK3831-A308 Long term safety extension study of ALKS3831 (MENT 35632) ENLIGHTEN	Range Agreed	1	10	Date Agreed	30/10/2021	1	30/10/2021	1	Recruitment Finished	Yes	
20/LO/1044	287176	A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults with Severe Postpartum Depression	Number Agreed	3	3	Date Agreed	28/02/2022	1	06/01/2022	1	Recruitment Finished	No	According to the Clinical Trial Agreement in our site "The Participating Organisation shall use its best endeavours to ensure that the Principal Investigator enrolls approximately three (3) Clinical Trial Subjects, to participate in the Clinical Trial and the Parties shall conduct the Clinical Trial in accordance with the Timelines". The PI of the study advised the sponsor that we would stop recruiting after enrolling one participant since the target was approximate.
18/LO/0575	213457	A Validation Study of a computerized, Artificial Intelligence assisted cognitive assessment test compared to a widely used cognitive assessment test and specialist clinical diagnosis in patients with Alzheimer's Dementia and Mild Cognitive Impairment	Number Agreed	30	30	Date Agreed	28/02/2022	35	21/02/2022	35	Recruitment Finished	Yes	
19/SC/0084	254209	BI 425809 with adjunctive CACT in schizophrenia (BI 1346-0038)	Number Agreed	5	5	Date Agreed	17/06/2022	2	17/06/2022	2	Recruitment Finished	No	The study has been very difficult to recruit to. It was struggling nationwide and recruitment was halted due to Covid. It was also impacted by turnover of recruiting staff. One of the main difficulties was that delivery team was looking for a participant to be stable. Many patients who had reached this stability didn't want to risk that by taking a new medication.